Short peptide bioregulator of cartilage origin. Studied in preclinical connective tissue research for potential effects on chondrocyte function and extracellular matrix homeostasis.
Cartalax is a research compound available through our china peptide catalog as a finished, lyophilized vial from an established Chinese manufacturer. It belongs to the Synthetic tetrapeptide bioregulator (cartilage origin)
Research Areas
Cartilage biology, chondrocyte research, ECM regulation, joint aging models, proteoglycan synthesis
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Cartalax | 20 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Chondrocyte Biology and ECM Research Research has examined cartalax’s effects on primary chondrocyte cultures and chondrocyte cell lines (ATDC5, SW1353) in terms of proteoglycan sulfation (DMMB assay), type II collagen immunohistochemistry, and aggrecan mRNA expression. These ECM synthesis endpoints are standard measures of anabolic chondrocyte activity. Research has also examined whether cartalax modulates MMP-13 and ADAMTS-5 — the primary cartilage-degrading enzymes — as an indicator of effects on the anabolic/catabolic balance. Joint Aging and Articular Cartilage Research Aging is the primary risk factor for articular cartilage degeneration. Research in aged rodent models has examined cartalax’s effects on articular cartilage morphology (safranin-O/fast green staining for proteoglycan content), chondrocyte density in weight-bearing zones, and synovial joint histology. These studies contribute to evaluation of peptide bioregulators as research tools in age-related musculoskeletal biology. Transcription and Epigenetic Mechanisms The proposed mechanism of tetrapeptide bioregulators like cartalax involves direct interaction with specific DNA regulatory sequences and chromatin-associated proteins, modulating transcription factor binding in tissue-specific gene promoters. Research probing this mechanism includes chromatin immunoprecipitation (ChIP) studies, gel-shift assays with cartilage-relevant gene promoter sequences, and epigenetic marker changes (H3K4 methylation, histone acetylation) in cartalax-treated chondrocytes. ## Sourcing Cartalax From China
Cartalax is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:
- Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
- Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
- Research-use discipline. Like every listing in our catalog, Cartalax is supplied for laboratory research use only, under strict research-use terms.
For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Cartalax | 20 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Chondrocyte Biology and ECM Research Research has examined cartalax’s effects on primary chondrocyte cultures and chondrocyte cell lines (ATDC5, SW1353) in terms of proteoglycan sulfation (DMMB assay), type II collagen immunohistochemistry, and aggrecan mRNA expression. These ECM synthesis endpoints are standard measures of anabolic chondrocyte activity. Research has also examined whether cartalax modulates MMP-13 and ADAMTS-5 — the primary cartilage-degrading enzymes — as an indicator of effects on the anabolic/catabolic balance. Joint Aging and Articular Cartilage Research Aging is the primary risk factor for articular cartilage degeneration. Research in aged rodent models has examined cartalax’s effects on articular cartilage morphology (safranin-O/fast green staining for proteoglycan content), chondrocyte density in weight-bearing zones, and synovial joint histology. These studies contribute to evaluation of peptide bioregulators as research tools in age-related musculoskeletal biology. Transcription and Epigenetic Mechanisms The proposed mechanism of tetrapeptide bioregulators like cartalax involves direct interaction with specific DNA regulatory sequences and chromatin-associated proteins, modulating transcription factor binding in tissue-specific gene promoters. Research probing this mechanism includes chromatin immunoprecipitation (ChIP) studies, gel-shift assays with cartilage-relevant gene promoter sequences, and epigenetic marker changes (H3K4 methylation, histone acetylation) in cartalax-treated chondrocytes.
Compound Profile
Cartalax (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed from research into peptide fractions of cartilage tissue. As part of the peptide bioregulator research program originating in Russian gerontology, it represents the minimal peptide sequence proposed to encode cartilage-specific gene regulatory activity — the concept that tissue-derived short peptides can interact with chromatin and regulate the expression of genes relevant to the tissue from which they are derived. Cartalax research focuses on chondrocyte function, extracellular matrix (ECM) maintenance, and cartilage biology. Research has examined cartalax in the context of articular cartilage degeneration models and chondrocyte culture systems. Studies have assessed its effects on proteoglycan synthesis, type II collagen expression, and matrix metalloproteinase (MMP) activity — the biochemical markers of cartilage anabolic versus catabolic balance. In aged rodent models, cartalax has been studied for effects on articular cartilage histomorphometry and chondrocyte survival following experimental joint stress. Proposed mechanisms involve transcription factor binding and epigenetic regulation of ECM-related gene promoters in chondrocytes. Peptides of China supplies Cartalax as a lyophilized powder at 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are for laboratory research use only and are not for human consumption.
Profile
Research Areas
Cartilage biology, chondrocyte research, ECM regulation, joint aging models, proteoglycan synthesis
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Cartalax | 20 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Chondrocyte Biology and ECM Research Research has examined cartalax’s effects on primary chondrocyte cultures and chondrocyte cell lines (ATDC5, SW1353) in terms of proteoglycan sulfation (DMMB assay), type II collagen immunohistochemistry, and aggrecan mRNA expression. These ECM synthesis endpoints are standard measures of anabolic chondrocyte activity. Research has also examined whether cartalax modulates MMP-13 and ADAMTS-5 — the primary cartilage-degrading enzymes — as an indicator of effects on the anabolic/catabolic balance. Joint Aging and Articular Cartilage Research Aging is the primary risk factor for articular cartilage degeneration. Research in aged rodent models has examined cartalax’s effects on articular cartilage morphology (safranin-O/fast green staining for proteoglycan content), chondrocyte density in weight-bearing zones, and synovial joint histology. These studies contribute to evaluation of peptide bioregulators as research tools in age-related musculoskeletal biology. Transcription and Epigenetic Mechanisms The proposed mechanism of tetrapeptide bioregulators like cartalax involves direct interaction with specific DNA regulatory sequences and chromatin-associated proteins, modulating transcription factor binding in tissue-specific gene promoters. Research probing this mechanism includes chromatin immunoprecipitation (ChIP) studies, gel-shift assays with cartilage-relevant gene promoter sequences, and epigenetic marker changes (H3K4 methylation, histone acetylation) in cartalax-treated chondrocytes.